The use of angiotensin system inhibitors correlates with longer survival in resected pancreatic adenocarcinoma patients.

Hao Liu,Ibrahim Nassour,Steven Lebowitz,Mark D'Alesio, Erica Hampton,Annissa Desilva,Abdulrahman Hammad,Samer AlMasri,Hussein H Khachfe,Aatur Singhi,Nathan Bahary,Kenneth Lee,Amer Zureikat,Alessandro Paniccia

HPB : the official journal of the International Hepato Pancreato Biliary Association（2022）

引用 1|浏览8

暂无评分

摘要

In this single-institution retrospective study focusing on resected PDAC patients, the use of ASI was associated with longer overall survival in multiple statistical models. Prospective clinical trials are needed before routine clinical implementation of ASI as an adjuvant to existing therapy can be recommended.

查看译文

关键词

PDAC,Renin-Angiotensin-Aldosterone System,angiotensin system inhibitors,pancreatic cancer

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要